Hims & Hers Health (NYSE:HIMS) Price Target Raised to $22.00

Hims & Hers Health (NYSE:HIMS) had its price target raised by Bank of America from $21.00 to $22.00 in a research report released on Tuesday morning,Benzinga reports. They currently have an underperform rating on the stock.

HIMS has been the subject of several other research reports. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Truist Financial increased their price target on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. Leerink Partners lifted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Trading Down 3.0 %

Shares of NYSE HIMS opened at $32.85 on Tuesday. The firm has a market cap of $7.30 billion, a P/E ratio of 74.67 and a beta of 1.37. The business’s 50 day moving average is $39.02 and its 200-day moving average is $28.55. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 4,213 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the sale, the chief financial officer now owns 128,365 shares in the company, valued at $3,848,382.70. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,015,547 shares of company stock worth $36,146,450 in the last ninety days. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. California State Teachers Retirement System grew its holdings in Hims & Hers Health by 18.8% during the 4th quarter. California State Teachers Retirement System now owns 166,337 shares of the company’s stock worth $4,022,000 after acquiring an additional 26,363 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth $213,000. IronOak Wealth LLC. bought a new stake in shares of Hims & Hers Health in the fourth quarter worth $922,000. Kilter Group LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth $1,053,000. Finally, Cim LLC increased its holdings in Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after purchasing an additional 694 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.